Key result
Pretreatment of antidigoxin antibodies with ouabain during binding to microbeads increased the digoxin binding capacity of hemoperfusion columns by 11-18 percent.
Why the study?
Does pretreatment with ouabain increase the digoxin binding capacity of antidigoxin antibody-based hemoperfusion columns?
Does pretreatment with ouabain increase the digoxin binding capacity of antidigoxin antibody-based hemoperfusion columns?
Protecting the active sites of antidigoxin antibodies with ouabain during column preparation increases digoxin binding capacity by 11-18%, optimizing hemoperfusion for digitalis intoxication.
May optimize hemoperfusion for digitalis intoxication; hypothesis-generating pending human validation.
Extracorporeal hemoperfusion through polyacrolein microsphere beads (APAMB) attached to antidigoxin antibodies is an effective treatment of digitalis intoxication. In order to increase the binding capacity of the APAMB columns the active sites of the antidigoxin antibodies were protected by ouabain during the binding to the microbeads. This brought about an 11-18 percent increase in digoxin binding capacity of the columns. It was also found that binding capacity does not increase with the rise of antibody concentration beyond a certain limit. Protection of antibody binding sites and determination of optimal concentration are, therefore necessary steps during preparation of antibody based hemoperfusion columns.
No takes yet. Share an insight, caveat, or question.
Savin et al. (1987) studied Digitalis intoxication. Pretreatment with ouabain was evaluated on Digoxin binding capacity of the columns (11-18 percent increase). Pretreatment of antidigoxin antibodies with ouabain during binding to microbeads increased the digoxin binding capacity of hemoperfusion columns by 11-18 percent.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: